New Single-Dose flu drug for kids shows promise in trial
NCT ID NCT07357051
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new medicine called JKN2301 for children aged 2 to 11 with the flu. It is a single-dose treatment compared to the standard 5-day oseltamivir (Tamiflu) course. The goal is to see if it safely reduces flu symptoms and fever faster. About 177 children will take part to check safety and how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JKN2301 dry suspension
What this could lead to
If it works, this could offer a new single-dose treatment option for children with the flu, potentially easing symptoms faster.
What could go wrong
This is an early phase 3 trial with only 177 children, so results may not apply to all. The drug could cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, 510000, China